Copertina

Editorial: Are changes in quantitative biliary metrics the first sign of progression in primary sclerosing cholangitis?

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	John E. Eaton, Sudhakar K. Venkatesh
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Quantitative MRCP and metrics of bile duct disease over time in patients with primary sclerosing cholangitis: A prospective study
di: Palak J. Trivedi, et al.
Pubblicazione: (2024)

Editorial: Unravelling real‐world impact of second‐line therapies in primary biliary cholangitis— Time to change our targets?
di: Guilherme Grossi Lopes Cançado
Pubblicazione: (2024)

Editorial: Is it time to include oral vancomycin in therapeutic guidelines for primary sclerosing cholangitis‐associated inflammatory bowel disease?
di: Ayesha Shah, et al.
Pubblicazione: (2024)

Letter: Microbial manipulation for primary sclerosing cholangitis‐associated inflammatory bowel disease—hope on the horizon
di: D. Bogatic, et al.
Pubblicazione: (2024)

Editorial: Unravelling real‐world impact of second‐line therapies in primary biliary cholangitis—Time to change our targets? Authors' reply
di: C. M. Fernández‐Rodríguez, et al.
Pubblicazione: (2024)

The overlap with metabolic dysfunction‐associated steatotic liver disease negatively affects outcomes of primary biliary cholangitis
di: María Hernández‐Pérez, et al.
Pubblicazione: (2024)

Letter: Fibrates may be safe and effective in patients with primary biliary cholangitis and decompensated cirrhosis—Authors' reply
di: Lukas Burghart, et al.
Pubblicazione: (2024)

Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis‐associated inflammatory bowel disease (PSC‐IBD): A matched analysis from the Paediatric PSC Consortium
di: Amanda Ricciuto, et al.
Pubblicazione: (2024)

Myokines are associated with progression, course and mortality in alcohol‐associated liver disease
di: Parminder Kaur, et al.
Pubblicazione: (2024)

Editorial: How does the risk of hepatocellular carcinoma change over time in patients with a hepatitis C cure? Authors' reply
di: Philip Vutien, et al.
Pubblicazione: (2024)

Editorial: DoesESWL‐ERCPfor pancreatic duct stone removal change the natural course of symptomatic chronic calcific pancreatitis?
di: Richard Kozarek
Pubblicazione: (2024)

Editorial: Intestinal Ultrasound for the Assessment of Constipation—Out of the Shadows?
di: J. M. B. W. Vos, et al.
Pubblicazione: (2025)

Editorial: DoesESWL‐ERCPfor pancreatic duct stone removal change the natural course of symptomatic chronic calcific pancreatitis? Authors' reply
di: Yu Liu, et al.
Pubblicazione: (2024)

Letter: Presence of progression or absence of response? Alternative trial designs for immunotherapy of advanced hepatocellular carcinoma
di: Enrico N. De Toni, et al.
Pubblicazione: (2024)

Editorial: Infliximab induction therapy in pediatric Crohn's disease—A cost‐effective strategy?
di: Neil Chanchlani, et al.
Pubblicazione: (2024)

Editorial: Redefining liver health—Personalised approach to assessment of serum ALT in clinical practice
di: Basile Njei, et al.
Pubblicazione: (2024)

Editorial: Obesity and Outcomes on Advanced Therapy in Ulcerative Colitis—The Fat of the Matter
di: Anish J. Kuriakose Kuzhiyanjal, et al.
Pubblicazione: (2025)

Editorial: Dual Advanced Therapy in Refractory Ulcerative Colitis—Hope Beyond Monotherapy
di: Ahmed B. Bayoumy, et al.
Pubblicazione: (2025)

Editorial: The microbiome and gastric mucosal protection in aspirin users—Authors' reply
di: Nina Løn, et al.
Pubblicazione: (2024)

Editorial: Intestinal Ultrasound for the Assessment of Constipation—Out of the Shadows? Authors' Reply
di: Ryan M. Mathias, et al.
Pubblicazione: (2025)

Editorial: Ulcerative Colitis Management in the Biologic Era–Data From the English Healthcare Databases. Authors' Reply
di: J. Couch, et al.
Pubblicazione: (2025)

Poor accuracy and sustainability of the first‐step FIB4 EASL pathway for stratifying steatotic liver disease risk in the general population
di: Antonio De Vincentis, et al.
Pubblicazione: (2024)

Editorial: Sonographic assessment of colonic content—A new tool for constipation? Authors' reply
di: R. M. Mathias, et al.
Pubblicazione: (2024)

Editorial: Reading the cholate—A new gateway to portal hypertension and oesophageal varices: Authors' reply
di: Tarek Hassanein, et al.
Pubblicazione: (2024)

Editorial: Quantity is important!
di: Chee‐Kiat Tan
Pubblicazione: (2024)

Editorial: High‐Grade Dysplasia in Colonic Inflammatory Bowel Disease Is Associated With a High Risk of Synchronous or Metachronous Colorectal Cancer—Authors' Reply
di: Monica E. W. Derks, et al.
Pubblicazione: (2025)

Editorial: Plants against animals
di: Einar S. Björnsson
Pubblicazione: (2024)

Editorial: Terlipressin Induced Bradycardia
di: Nancy Reau, et al.
Pubblicazione: (2025)

Editorial: Optimal Treatment for Older Patients With Inflammatory Bowel Disease: How to Detect and Manage Frailty? Authors' Reply
di: A. B. Fons, et al.
Pubblicazione: (2026)

Editorial: Quantity is important! Authors' reply
di: Marika Rudler, et al.
Pubblicazione: (2024)

Editorial: Another brick in the CDST wall
di: Aurelien Amiot, et al.
Pubblicazione: (2024)

Editorial: Upadacitinib in Perianal Crohn's Disease
di: Manjeet Kumar Goyal, et al.
Pubblicazione: (2026)

Editorial: Getting to the Heart of the Matter in IBD
di: Ashwin N. Ananthakrishnan
Pubblicazione: (2025)

Editorial: Gastrointestinal symptoms—A world of differences
di: Kevin W. Olden
Pubblicazione: (2024)

Editorial: Allostatic Load and Inflammatory Bowel Disease
di: Jeli Mendoza, et al.
Pubblicazione: (2024)

Editorial: Muscles at the expense of liver injury. Is it worth it?
di: C. Stephens
Pubblicazione: (2024)

Editorial: To Stop Or Not To Stop: Is It Still A Question?
di: Stephan R. Vavricka, et al.
Pubblicazione: (2024)

Editorial: Defining corticosteroid use in clinical trials
di: J. Siffledeen
Pubblicazione: (2024)

Editorial: Cardiometabolic criteria matters inMASLD
di: Margaret L. P. Teng, et al.
Pubblicazione: (2024)

Editorial: Striving for Equitable Care in Ulcerative Colitis
di: Edward L. Barnes
Pubblicazione: (2025)